When human cells are stressed during G2, they are delayed from entering mitosis via a checkpoint mediated by the p38 kinase [1] [2] [3] [4] [5] , and this delay can be modeled by the selective activation of p38 with anisomycin [6, 7] . Here, we report, on the basis of live-cell studies, that 75 nM anisomycin transiently (1 hr) activates p38 which, in turn, rapidly and completely blocks entry into mitosis for at least 4 hr in all primary, telomeraseor spontaneously immortalized (p53+ and pRB+) human cells. However, the same treatment does not delay entry into mitosis in cancer cells, or the delay in entering mitosis is shortened, even though it induces a similar transient and comparable (or stronger) activation of p38. Because the primary substrate of p38, the MK2 kinase, is also transiently (1-2 hr) activated by anisomycin in both normal and cancer cells, checkpoint disruption in transformed cells occurs downstream of MK2. Finally, observations on isogenic lines reveal that the duration of the stress checkpoint is shortened in cells lacking both p53 and pRb and that the constitutive expression of an active H-Ras oncogene in these cells further attenuates the checkpoint via an ERK1/2-dependent manner. Thus, transformation leads to attenuation of the p38-mediated stress checkpoint. This outcome is likely selected for during transformation because it confers the ability to outgrow normal cells under stressful in vitro (culture) or in vivo (tumor) environments. Our data caution against using cancer cells to study how p38 produces a G2 arrest.
Results and Discussion
We used two time-lapse light microscopic (LM) assays to study how the activation of p38 affects the G2-M transition. The first is based on the observation that the cessation of chromosome condensation in late G2 reveals that the cell cycle has been arrested [8] . The second is based on the fact that the number of cells entering mitosis during a given 30 min period can be accurately determined in monolayer cultures from 103 phase-contrast records of cell fields ( Figure S1 in the Supplemental Data available online). (The number of experiments for our studies and the number of cells examined is tabulated in Table S1 .) In both assays, cells entered mitosis with normal kinetics when treated with only dimethyl sulfoxide (DMSO) ( Figure S2C ).
Activating p38 in Normal Cells Rapidly Delays the G2-M Transition
The antibiotic anisomycin is a well-studied proteinsynthesis inhibitor that activates p38 but not JNK (Figure 1 ) at nM concentrations in cultured cells [6, 7] with minimal effects on protein translation [9, 10] . We found that the G2 delay induced by anisomycin increased with increasing drug concentrations ( Figure S2A ), which activated correspondingly more p38 (Figure 1 ; see also [7] ). From these data, we defined an anisomycin concentration (75 nM; Figure S2A ) that delayed the G2-M transition for at least 4 hr in normal human cells (Figure 2A ) without activating JNK kinase (Figure 1 ). Under this condition, the number of cells entering mitosis falls at least 3-fold within 30 min of anisomycin treatment (Figure 2A ), until it reaches zero by 1 hr. Accordingly, when late G2 hTERT-RPE1 cells were perfused with 75 nM anisomycin early in chromosome condensation, entry into mitosis was delayed ( Figure 2C ; n = 6).
To confirm that this G2 delay requires p38 activity, we incubated hTERT-RPE1 cultures in 25 mM SB203580, a potent inhibitor of p38 activation [11] , 30 min before treating them with anisomycin. As expected under this condition, RPE1 cells entered mitosis after exposure to 75 nM anisomycin, although the combination of drugs did slightly depress the rate ( Figure S2B ).
After 4 hr or more in 75 nM anisomycin, normal cells resumed cycling into mitosis (Figure 2A , Figure S2A ). However, rather than quickly reaching control levels, the mitotic index increased gradually ( Figure S2D ), implying that the activation of p38 stops G2 at that point at which the drug was applied and that different cells recover at different rates. Although under our conditions the mitotic index did not return to control levels, when normal cells are stressed with agents that have no long-term, toxic side effects (e.g., nocodazole or osmotic shock), the mitotic index quickly returns to control levels [4, 12] .
To determine whether p38 activity remains high as cells slip through the stress checkpoint, we assayed p38 activity over time in telomerase-immortalized RPE1 and BJ-EN cells exposed continuously to anisomycin. In both lines, p38 activity rose during the first hour of treatment to levels more than five times that of nontreated cells, after which it quickly decayed to pretreatment levels (cf. Figure 1B , Figure S3 ). This anisomycin-induced spike and subsequent decay of p38 activity has been noted by others [13] . As for osmotic shock [4] , we also found that the inhibition of p38 with SB203580, 1 hr after it was activated with 75 nM anisomycin, did not significantly accelerate entry into mitosis in RPE1 cells (p = < 0.001; data not shown). Thus, as noted by Dmitrieva and colleagues [4] , although a sudden increase in p38 activity is required for the initiation of a stress-induced G2 delay, the delay is maintained by downstream events independent of p38. Several feedback control loops are thought to limit the duration of p38 activation [14] , most likely to insure an adequate response to subsequent stresses.
At this point, we can define several characteristics of the p38-mediated checkpoint pathway in normal cells. First, when triggered, it stops progression through G2 in minutes. Second, in a normal cell population, the checkpoint is rigorous: Not one cell out of many thousands was seen to enter mitosis 30 min after the activation of p38. Third, although p38 activity is required to trigger the G2 delay, downstream events maintain the delay. Finally, after a variable period, G2 cells resume cycling into mitosis in the presence of the activating stress.
Activating p38 in Cancer Cells Does Not Delay Entry into Mitosis, or Delay Is Significantly Reduced Next, we explored how the activation of p38 affects the G2-M transition in cancer cells. p38 is readily activated in many cancer lines [6] , including those used in our study, e.g., CFPAC1 [15] , tumorigenic (T)-HEP3, and D dormant (D)-HEP3 [16] . For HeLa cells, we found that 75 nM anisomycin activated p38 to a much higher level than it did in nontransformed REP1 cells ( Figure 1B ). Yet although anisomycin strongly activates p38 in the cancer lines examined, cells in these lines continued to enter mitosis after drug treatment ( Figure 2B ). In T-HEP3 and D-HEP3, the rate of entry did not appreciably change relative to controls, whereas in HeLa, CFPAC1, HT 1080, and MCF7 (data not shown), the rate was depressed to different extents. However, in no line was entry into mitosis completely blocked for 4 hr, as in normal cells.
Do those cancer cells that enter mitosis after the activation of p38 do so because they define a subpopulation that lacks a checkpoint response, or does anisomycin delay G2 equally in all cells? To answer this question, we located early prophase cells in HeLa cultures and perfused them with anisomycin. All of these cells (n = 7) entered mitosis with normal timing ( Figure 2C ). Thus, cells that progress into mitosis after the activation of p38 in cancer lines do so because the stress-checkpoint response is attenuated.
Eliminating Both p53 and pRb Attenuates the Duration of the p38-Mediated Stress Checkpoint by Enhancing the Rate of Slippage Because entry into mitosis is delayed 4-5 hr after the activation of p38 in normal BJ and hTERT immortalized (RPE1 and BJ-EN) cells, immortalization per se does not attenuate the stress checkpoint. To determine whether p53 is involved in this process, we treated human cells in which p53 was either genetically inactivated (HMEC184AA2) or inactivated by human papillomavirus type 16 (HPV-16) E6 expression (E6 keratinocytes) with anisomycin. In these lines, anisomycin still significantly retarded entry into mitosis, although the delay was slightly shorter (3-4 hr versus 4-4.5 hr; cf., Figures 2A  and 3A ) than in the p53+ parental controls. (Consistent with this, we found that p21Cip1, a potent cyclin-dependent kinase inhibitor regulated by p53, is not induced when RPE1 or BJ-EN cultures are treated with anisomycin [data not shown]). Thus, the stress checkpoint remains largely functional in cells that have undergone the two early stages of transformation (viz., telomerase immortalization and p53 inactivation).
The inactivation of both p53 and pRb by the expression of viral oncoproteins produces full transformation in many cell types. We found that the activation of p38 in cultures of keratinocytes expressing HPV-16 E6 and E7, which lack p53 and pRb, only briefly delayed the G2-M transition ( Figure 3A) , and the cells resumed cycling into mitosis w90 min after drug treatment. Furthermore, after 3.5 hr, the rate cells entered mitosis in these cultures was not statistically different from that of untreated cells ( Figure 3A) . To determine whether E7's Table  S1 ) 6 the standard error of the mean (SEM). Typically, 7 min elapsed between the addition of the drug to the initiation of recordings. Note that the activation of p38 rapidly and completely inhibits entry into mitosis (the G2-M transition) for at least 4 hr in normal cells (A) but to a much lesser extent in tumor cells (B). (C) The behavior of normal (RPE1) and cancer (HeLa) cells after the activation of p38 with anisomycin during late G2. RPE1 (top) and HeLa (bottom) cells in the early stages of chromosome condensation (arrows at 0 and 10 min, top panel) were located within a culture and followed by timelapse imaging. Ten minutes into imaging, the cultures were perfused with 75 nM anisomycin (see the Supplemental Experimental Procedures). The activation of p38 in RPE1 cells rapidly arrests progression through G2 and reverses chromosome condensation (compare chromosomes at 20 versus 10 min, top panel, arrows). In contrast, after the activation of p38 in HeLa cells (bottom panel), chromosome condensation continued normally, and nuclear-envelope breakdown (NEB) occurred, as in nontreated controls, w50 min later. The scale bar represents 10 mM. involvement in this checkpoint attenuation is due to pRb inhibition and not E7's acting on other substrates, we used an E7 mutant (E7.24) that does not inhibit pRb but that is functionally normal in all other respects [17] . For this study, we treated cultures of keratinocytes expressing E7.24 with anisomycin and examined them at hourly intervals. As observed in control keratinocytes, we found that the activation of p38 in E7.24 cells blocked entry into mitosis for at least 4 hr (data not shown). Thus, E7 leads to stress-checkpoint attenuation by inhibiting pRb and not other substrates.
We also found that the G2-M transition was only briefly (i.e., for w1.5 hr; Figure 3A ) delayed when p38 was activated in hTERT-immortalized BJ fibroblasts lacking p53 and pRB (BJ-ELB cells) because of SV40 large-T oncoprotein [18] or E6E7 [19] expression. However, unlike E6 and E7 keratinocytes, these fibroblasts resumed cycling into mitosis after 1.5 hr at a very low rate for the duration of the experiment. (A Student's t test comparison of the recovery rates between BJ-EN and BJ-ELB cells during the first 3 hr of anisomycin treatment reveals that they are significantly different, Figure 3 . Attenuation of the p38-Mediated Delay in Entering Mitosis Occurs during Oncogenic Transformation (A) Graphic representations from population studies (described in Figure 1) depicting the rate at which cells enter mitosis in cultures of immortalized mammary epithelia that contain (HMEC184A1) or lack (HMEC184AA2) a functional p53. Similar analyses were conducted on human keratinocytes lacking functional p53 (E6) or lacking both p53 and pRB (E6E7), as well as in hTERT-immortalized BJ fibroblasts containing (BJ-EN) or lacking (BJ-ELB) p53 and pRB or lacking p53 and pRB but expressing V12Ras (BJ-ELR). In general, the sustainability (duration) of the G2 delay induced by the activation of p38 decreases with increasing degrees of transformation. The percentages represent the average from several experiments (for n, see Table S1 ) 6 the SEM. (B) Western blot depicting dually phosphorylated and activated p38 (p38-T*GY*) versus total p38 loading control (bottom panel) in BJ-ELR cells. Samples were prepared 30 min after the incubation of cultures in media plus DMSO FOR 30 min or for various times in media containing 75 nM anisomycin (dissolved in DMSO). (C) Similar to (B) except these blots show the activity of p38 as well as its downstream target, MK2, over 8 hr. Note that in response to anisomycin, both p38 and MK2 are strongly activated in BJ-ELR cells within the first hour but both then decline to near pretreatment levels during the second hour.
with p < 0.05.) Similar results were seen in other SV-40-transformed cell lines, including the GM16666A and GM16667A (NIGMS) human fibroblasts (data not shown). Together, these observations reveal that the elimination of p53 and pRb, with human papillomavirus E6 and E7 and/or the large-T of SV40, can lead to significant attenuation of the p38-mediated G2 stress checkpoint by enhancing the rate of slippage.
Constitutive Ras Signaling Further Attenuates the p38 Stress Checkpoint in Cells Lacking pRB and p53
Mutations that constitutively activate Ras are frequent in cancers and lead to high ERK1 and 2 activity [20] . Some tumor lines used in our study exhibit high ERK activity (T-HEP3, CFPAC1), and some harbor constitutively activated Ras (CFPAC1, HT-1080). ERK is constitutively activated when H-RasV12 is introduced into BJ-ELB (-p53 and -pRb) fibroblasts [19] , and the resultant BJ-ELR cells become fully tumorigenic [18] . We found that BJ-ELR cells responded slower to p38 activation than did their parental (BJ-ELB) controls, exhibiting only a 50% reduction in the number of cells entering mitosis after 30 min ( Figure 3A) . Furthermore, unlike what was observed in control cells, the activation of p38 never prevented all BJ-ERL cells from entering mitosis because even after 1 hr, 0.03 6 0.03% of the cells continued to cycle into division, and this rate progressively increased after 30 min until it approached control levels 4 hr later ( Figure 3A) .
Given this result, it became important to determine the extent to which anisomycin activates p38 in Rasexpressing BJ-ELR cells. Constitutive Ras activity does not prevent p38 activation in immortal p53-pRB cells [19] , and stress activates p38 in oncogenic Ras-expressing cells, in which ERK is constitutively active [21] . Not surprisingly, therefore, we found ( Figure 3C ) that a 5 min treatment with 75 nM anisomycin produced an w10-fold increase in p38 activity in BJ-ERL cells, which greatly exceeded that seen in normal BJ-EN cells ( Figure S3 ), after which it decayed to levels near background. Thus, as in HeLa (Figure 1) , the attenuation of the G2 stress checkpoint in BJ-ELR fibroblasts is due to a disruption between p38 and its cdc25 and CDK1 target.
Together, these data reveal that the activation of p38 in fully transformed (BJ-ELR) fibroblasts briefly and incompletely inhibits the G2-M transition. Moreover, because BJ-ELR fibroblasts, T-Hep3 ( Figure 2B ), and E6E7 keratinocytes ( Figure 3A) cycle into mitosis at relatively normal rates 4-5 hr after anisomycin treatment, the drug-induced reduction in protein synthesis is insufficient during this period to prevent the G2-M transition.
ERK1 and 2 Kinase Activity Is Required for the Ras-Mediated Attenuation of the Stress Checkpoint in Cells Lacking pRB and p53
The ERK1 and 2 group of MAP kinases promotes cellcycle progression after radiation-induced DNA damage [22] , and high ERK1 and 2 activity is necessary for Rasinduced chromosomal instability [23] . This prompted us to ask whether hyperfunction of the Ras-Raf-MEK1 and 2-ERK1 and 2 signaling cascade participates in attenuating the stress checkpoint in BJ-ELR cells. To answer this question, we blocked ERK activity in these cells before activating p38. Because the H-Ras-V12 oncogene significantly enhances ERK1 and 2 activity in BJ-ELR cells [19] , these cells required higher inhibitor concentrations than nontransformed cells to suppress ERK1 and 2. In this regard, we found that a 3 hr treatment with 400 mM U0126 completely inhibited ERK1 and 2 in BJ-ELR cells for at least 7 hr ( Figure 4A ). As expected [11] , U0126 slightly depressed p38 activity during the first 3 hr, but this returned to control levels by the fourth hour ( Figure 4A ). During the first 5 hr in U0126, the rate at which BJ-ELR cells entered mitosis was also nominally depressed, but it too returned to control levels after this time (the 2 hr mark in Figure 4A 0 ). (Because we also observed this transient decrease in the rate at which BJ-ELR cells enter mitosis in response treatment with a nonfunctional analog of U0126 (U0124; Figure 4B 0 ), we attribute it to nonspecific effects.) Importantly, however, we found that when BJ-ELR cultures were treated with anisomycin 3 hr after the inhibition of ERK1 and 2 with U0126, the rate at which cells entered mitosis dropped to zero for 3 hr ( Figure 4A 0 ). We then repeated this experiment with U0124, an inactive analog of U0126, and found that anisomycin treatment neither reduced ERK1 and 2 activity ( Figure 4B ) nor delayed entry into mitosis any more than did anisomycin treatment alone (cf. Figures 3A, 4A 0 , and 4B 0 ). Thus, excessive ERK1 and 2 activity in cells constitutively expressing the Ras oncogene contributes to the attenuation of the p38 stress checkpoint. Additional work with CI-1040, a much more potent and specific ERK1 and 2 inhibitor [24] , further substantiated this conclusion ( Figures 4C and 4C 0 ): Simply the reduction of ERK1 and 2 activity in BJ-ELR cells to levels seen in nontransformed cells during late G2 [25] also prolongs the G2 block induced by the activation p38.
MAPKAP kinase-2 (MK2) is the major downstream target of the p38 pathway. Activated MK2 can modify gene expression [26] , depress translation [27] , and delay G2 progression independent of the Chk1 kinase by indirectly inhibiting the Cdc25 phosphatase [28] . To determine whether stress-checkpoint abrogation in BJ-ELR (and other transformed) cells results from a failure of p38 to activate MK2, we assayed MK2 levels after activating p38. As for p38, we found that MK2 is strongly but transiently (1 hr) activated by anisomycin in BJ-ELR and other cancer cells ( Figure S3 ). The fact that 75 nM anisomycin induces both a 1 hr activation of MK2 (Figure 3D ) and an w1 hr G2 delay in BJ-ELR ( Figure 3A) suggests that the duration of the stress checkpoint is defined by MK2 activity. This is consistent with the report that the sustained (more than 8 hr) activation of p38 and MK2 induced by doxorubicin (a topoisomerase II inhibitor) in U2OS cells produces a sustained (more than 8 hr) S-G2 arrest [28] . However, in RPE1 cells, 75 nM anisomycin leads to an w2 hr activation of MK2 ( Figure S3 ), yet it produces a 4 hr delay in G2 (Figure 2) . Clearly, the role of MK2 in regulating the duration of the stress checkpoint requires further study.
In summary, relative to normal cells, the p38-mediated stress checkpoint is attenuated in transformed cells. Although our data implicate Ras signaling and ERK1 and 2 activity in the attenuation process, how these pathways ultimately disrupt the Cdc25-mediated [3, 29] suppression of CDK1 to effect a G2 delay remains unclear. In retrospect, the loss of the stress checkpoint during transformation is not unexpected: Any mutation in a cell-cycle brake will confer a selective growth advantage over normal cells, and mutations(s) in a brake activated by stress will, by Darwinian selection [30] , make it easier for the cell to outgrow normal cells under the increasingly stressful conditions (e.g., hypoxia, high pH, etc.) in a tumor. This is likely true also for cells in culture, where mutations in tumor suppressers like pRb or p53 promote, over generations, genetic changes that provide a selective growth advantage under stress. Epithelial cancers induced by chronic environmental stress, notably Barrett's esophageal and cervical dysplasias, are well known clinical examples. At this time, the clinical relevance of our conclusions remains unclear, but because our data implicates the ERK1 and 2 MAPK pathway in stress-checkpoint attenuation, ERK1 and 2 inhibitors (which are under clinical trials) might slow the growth of tumor cells by potentiating the stress checkpoint. Figure 3A) . (B and B 0 ) Same conditions as in (A) and (A 0 ) except that U0126 was replaced by its inactive analog, U0124 (400 mM). Note that this analog neither inhibits ERK1 and 2 nor prolongs the G2 block after the activation of p38 with anisomycin (cf. Figure 4A ). (C and C 0 ) Same conditions as in (A) and (A 0 ) except that U0126 was replaced by 600 nM CI-1040, a more potent and specific ERK1 and 2 inhibitor. The concentration of CI-1040 used in this study reduced ERK1 and 2 activity to that which approximates the level seen in normal G2 cells [25] . Under this condition, the activation of p38 with anisomycin completely inhibits entry into mitosis for at least 2 hr (cf. Figure 4A) . The percentages represent the average from several experiments (for n, see Table S1 ) 6 the SEM.
